Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763608 | 0.80 | TSHR (0.42) | ALDH1A1L3MBTL1TSHRGABRA1GABRB2 | |
| SCHEMBL4101476 | 0.79 | GABRA1 (0.44) | ALDH1A1L3MBTL1TSHRGABRA1GABRB2 | |
| SCHEMBL23252274 | 0.75 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL2163244 | 0.75 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1TSHR | |
| SCHEMBL12696836 | 0.75 | CYP2D6 (0.45) | ALDH1A1GABRA1GABRB2 | |
| SCHEMBL1626479 | 0.74 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1TSHR | |
| SCHEMBL1626819 | 0.74 | LMNA (0.38) | ALDH1A1GABRA1GABRB2 | |
| SCHEMBL29433705 | 0.72 | ESR1 (0.46) | ALDH1A1TSHRGABRA1GABRB2 | |
| SCHEMBL954806 | 0.72 | ESR1 (0.46) | ALDH1A1TSHRGABRA1GABRB2 | |
| SCHEMBL26025303 | 0.72 | CYP2D6 (0.38) | ALDH1A1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | ALDH1A1 128/4885L3MBTL1 4364/4885TSHR 4328/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | ALDH1A1 128/4885L3MBTL1 4364/4885TSHR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.